Shire strategy fails to keep predators at bay; The UK-listed, Dublin-based speciality drugmaker has long been touted as an attractive prize – especially for US rivals drawn to Ireland’s low corporate tax rate
June 8, 2014 Leave a comment
June 2, 2014 10:11 pm
Shire strategy fails to keep predators at bay
By Andrew Ward, Arash Massoudi and Neil Hume
When bankers talk about the deal frenzy gripping the pharmaceuticals sector, it rarely takes long for Shire’s name to come up as a potential target.
The UK-listed, Dublin-based speciality drugmaker has long been touted as an attractive prize – especially for US rivals drawn to Ireland’s low corporate tax rate.
However, Flemming Ornskov, chief executive, is doing his best to cast Shire as predator rather than prey.
Less than six months after completing its $4.2bn takeover of ViroPharma and two weeks after a $260m deal to buy Lumena, Shire is looking to complete a hat trick of acquisitions in the US rare disease sector. Read more of this post











